These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 22044225)

  • 1. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.
    Garg H; Viard M; Jacobs A; Blumenthal R
    Curr Top Med Chem; 2011 Dec; 11(24):2947-58. PubMed ID: 22044225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development.
    Jacobs A; Garg H; Viard M; Raviv Y; Puri A; Blumenthal R
    Vaccine; 2008 Jun; 26(24):3026-35. PubMed ID: 18242797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
    Lu L; Yu F; Cai L; Debnath AK; Jiang S
    Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
    Platt EJ; Gomes MM; Kabat D
    J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.
    Joshi A; Nyakeriga AM; Ravi R; Garg H
    J Biol Chem; 2011 Oct; 286(42):36404-13. PubMed ID: 21859712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization.
    Huarte N; Lorizate M; Pérez-Payá E; Nieva JL
    Curr Top Med Chem; 2011 Dec; 11(24):2985-96. PubMed ID: 22044227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants.
    Garg H; Joshi A; Blumenthal R
    AIDS Res Hum Retroviruses; 2009 Aug; 25(8):811-7. PubMed ID: 19619009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H; Otaka A; Fujii N
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
    Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
    J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipophilic and amphiphilic interactions in glycoprotein 41: targets for therapy.
    Gochin M
    Curr Top Med Chem; 2011 Dec; 11(24):2945-6. PubMed ID: 22044224
    [No Abstract]   [Full Text] [Related]  

  • 16. Amphipathic properties of HIV-1 gp41 fusion inhibitors.
    Gochin M; Zhou G
    Curr Top Med Chem; 2011 Dec; 11(24):3022-32. PubMed ID: 22044226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion.
    Garg H; Joshi A; Freed EO; Blumenthal R
    J Biol Chem; 2007 Jun; 282(23):16899-906. PubMed ID: 17416587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
    Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
    Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a future for antiviral fusion inhibitors?
    Berkhout B; Eggink D; Sanders RW
    Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.